Loading
A phase 1 trial of CBA-1535 run by Chiome Bioscience Inc., now recruiting.
A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. is a phase 1 interventional study registered as NCT07016997 by Chiome Bioscience Inc., with 70 participants planned, started 2022-06-27. Conditions recorded: Solid Tumors and Refractory Cancer. Interventions recorded: CBA-1535 and CBA-1535+Pembrolizumab.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/